Shenzhen Salubris Pharmaceuticals Co Ltd
Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines and medical devices in China. The company offers drugs for various therapeutic fields, such as thrombosis, hypertension and related diseases, osteoporosis, and infections, as well as anti-osteolysis, antiallergic, antiepileptic, and antidepressant medicines. It also develops Sacubit… Read more
Market Cap & Net Worth: Shenzhen Salubris Pharmaceuticals Co Ltd (002294)
Shenzhen Salubris Pharmaceuticals Co Ltd (SHE:002294) has a market capitalization of $8.90 Billion (CN¥65.31 Billion) as of March 18, 2026. Listed on the SHE stock exchange, this China-based company holds position #3569 globally and #301 in its home market, demonstrating a 19.31% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shenzhen Salubris Pharmaceuticals Co Ltd's stock price CN¥58.58 by its total outstanding shares 1114816535 (1.11 Billion).
Shenzhen Salubris Pharmaceuticals Co Ltd Market Cap History: 2015 to 2026
Shenzhen Salubris Pharmaceuticals Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $3.85 Billion to $8.90 Billion (9.24% CAGR).
Shenzhen Salubris Pharmaceuticals Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shenzhen Salubris Pharmaceuticals Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.17x
Shenzhen Salubris Pharmaceuticals Co Ltd's market cap is 1.17 times its annual revenue
1.02x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
7.81x
Shenzhen Salubris Pharmaceuticals Co Ltd's market cap is 7.81 times its annual earnings
10.35x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.85 Billion | $3.48 Billion | $1.27 Billion | 1.11x | 3.04x |
| 2016 | $3.82 Billion | $3.83 Billion | $1.40 Billion | 1.00x | 2.74x |
| 2017 | $6.05 Billion | $4.15 Billion | $1.45 Billion | 1.46x | 4.17x |
| 2018 | $2.85 Billion | $4.65 Billion | $1.46 Billion | 0.61x | 1.96x |
| 2019 | $2.81 Billion | $4.47 Billion | $715.20 Million | 0.63x | 3.92x |
| 2020 | $4.09 Billion | $2.74 Billion | $60.86 Million | 1.49x | 67.22x |
| 2021 | $3.95 Billion | $3.06 Billion | $533.73 Million | 1.29x | 7.39x |
| 2022 | $4.83 Billion | $3.48 Billion | $637.09 Million | 1.39x | 7.59x |
| 2023 | $4.87 Billion | $3.37 Billion | $580.07 Million | 1.45x | 8.40x |
| 2024 | $4.70 Billion | $4.01 Billion | $601.57 Million | 1.17x | 7.81x |
Competitor Companies of 002294 by Market Capitalization
Companies near Shenzhen Salubris Pharmaceuticals Co Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Shenzhen Salubris Pharmaceuticals Co Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Shenzhen Salubris Pharmaceuticals Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Shenzhen Salubris Pharmaceuticals Co Ltd's market cap moved from $3.85 Billion to $ 8.90 Billion, with a yearly change of 9.24%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥8.90 Billion | +18.22% |
| 2025 | CN¥7.53 Billion | +60.20% |
| 2024 | CN¥4.70 Billion | -3.57% |
| 2023 | CN¥4.87 Billion | +0.82% |
| 2022 | CN¥4.83 Billion | +22.52% |
| 2021 | CN¥3.95 Billion | -3.56% |
| 2020 | CN¥4.09 Billion | +45.79% |
| 2019 | CN¥2.81 Billion | -1.65% |
| 2018 | CN¥2.85 Billion | -52.86% |
| 2017 | CN¥6.05 Billion | +58.26% |
| 2016 | CN¥3.82 Billion | -0.77% |
| 2015 | CN¥3.85 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Shenzhen Salubris Pharmaceuticals Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.90 Billion USD |
| MoneyControl | $8.90 Billion USD |
| MarketWatch | $8.90 Billion USD |
| marketcap.company | $8.90 Billion USD |
| Reuters | $8.90 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.